PubMed:23396402 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/23396402","sourcedb":"PubMed","sourceid":"23396402","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23396402","text":"Thrombosis of the portal venous system.\nPortal vein thrombosis (PVT) is a rare cause of portal hypertension. Its diagnosis has been facilitated by improvements in imaging techniques, in particular Doppler sonography. The prevalence is about 1% in the general population, but much higher rates are observed in patients with hepatic cirrhosis (7%, range 0.6-17%), particularly those who also have hepatocellular carcinoma (HCC) (35%). The most common causes of PVT are myeloproliferative disorders, deficiencies of anticoagulant proteins, prothrombotic gene mutations, cirrhosis with portal hypertension, and HCC. Its development often requires the presence of two or more risk factors (local and/or systemic), e.g., a genetically determined thrombophilic state plus an infectious episode or abdominal surgery. It is clinically useful to distinguish between cirrhotic and noncirrhotic forms. Portal vein thrombosis is also traditionally classified as acute or chronic, but this distinction is often difficult. Color Doppler ultrasound is the first-line imaging study for diagnosis of PVT; magnetic resonance angiography and CT angiography are valid alternatives. The main complications are ischemic intestinal necrosis (in acute PVT) and esophageal varices (in chronic cases); the natural history of the latter differs depending on whether or not the thrombosis is associated with cirrhosis. The treatment of choice for PVT has never been adequately investigated. It is currently based on the use of anticoagulants associated, in some cases, with thrombolytics, but experience with the latter agents is too limited to draw any definite conclusions. In chronic thrombosis (even forms associated with cirrhosis), anticoagulant therapy is recommended and possibly, beta-blockers as well. Naturally, treatment of the underlying pathology is essential.","tracks":[{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":40,"end":62},"obj":"HP_0030242"},{"id":"T2","span":{"begin":88,"end":107},"obj":"HP_0001409"},{"id":"T3","span":{"begin":95,"end":107},"obj":"HP_0000822"},{"id":"T4","span":{"begin":323,"end":340},"obj":"HP_0001394"},{"id":"T5","span":{"begin":331,"end":340},"obj":"HP_0001394"},{"id":"T6","span":{"begin":395,"end":419},"obj":"HP_0001402"},{"id":"T7","span":{"begin":467,"end":495},"obj":"HP_0005547"},{"id":"T8","span":{"begin":567,"end":576},"obj":"HP_0001394"},{"id":"T9","span":{"begin":582,"end":601},"obj":"HP_0001409"},{"id":"T10","span":{"begin":589,"end":601},"obj":"HP_0000822"},{"id":"T11","span":{"begin":890,"end":912},"obj":"HP_0030242"},{"id":"T12","span":{"begin":1379,"end":1388},"obj":"HP_0001394"},{"id":"T13","span":{"begin":1697,"end":1706},"obj":"HP_0001394"}],"attributes":[{"subj":"T1","pred":"source","obj":"PubmedHPO"},{"subj":"T2","pred":"source","obj":"PubmedHPO"},{"subj":"T3","pred":"source","obj":"PubmedHPO"},{"subj":"T4","pred":"source","obj":"PubmedHPO"},{"subj":"T5","pred":"source","obj":"PubmedHPO"},{"subj":"T6","pred":"source","obj":"PubmedHPO"},{"subj":"T7","pred":"source","obj":"PubmedHPO"},{"subj":"T8","pred":"source","obj":"PubmedHPO"},{"subj":"T9","pred":"source","obj":"PubmedHPO"},{"subj":"T10","pred":"source","obj":"PubmedHPO"},{"subj":"T11","pred":"source","obj":"PubmedHPO"},{"subj":"T12","pred":"source","obj":"PubmedHPO"},{"subj":"T13","pred":"source","obj":"PubmedHPO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"PubmedHPO","color":"#ec93b0","default":true}]}]}}